Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiencesBernardo Rossini, Attilio Guarini, Roberto Massaiu et al.|Drugs in Context|2014Cited by 3
Corrigendum: Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiencesBernardo Rossini, Attilio Guarini, Nicola Cecchi et al.|Drugs in Context|2024Cited by 3
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohortAndrea Serafin, Andrea Visentin, Alessandro Cellini et al.|Blood Advances|2025Cited by 3
Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practiceAnna Maria Frustaci, Lara Crucitti, Andrea Galitzia et al.|Haematologica|2025Cited by 2
A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 TrialLydia Scarfò, Paolo Ghia, Marta Coscia et al.|Blood|2023Cited by 1